1. Home
  2. TILE vs ANAB Comparison

TILE vs ANAB Comparison

Compare TILE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interface Inc.

TILE

Interface Inc.

HOLD

Current Price

$28.89

Market Cap

1.6B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$50.76

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TILE
ANAB
Founded
1973
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
TILE
ANAB
Price
$28.89
$50.76
Analyst Decision
Buy
Buy
Analyst Count
1
12
Target Price
$36.00
$71.67
AVG Volume (30 Days)
517.8K
559.1K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
0.29%
N/A
EPS Growth
32.43
91.02
EPS
0.40
N/A
Revenue
$1,386,854,000.00
$234,603,000.00
Revenue This Year
$6.72
N/A
Revenue Next Year
$5.61
$52.14
P/E Ratio
$71.95
N/A
Revenue Growth
5.41
157.01
52 Week Low
$20.01
$17.11
52 Week High
$35.11
$73.30

Technical Indicators

Market Signals
Indicator
TILE
ANAB
Relative Strength Index (RSI) 52.05 29.84
Support Level $26.60 $43.75
Resistance Level $28.89 $51.67
Average True Range (ATR) 1.02 2.93
MACD -0.02 -1.23
Stochastic Oscillator 58.14 1.45

Price Performance

Historical Comparison
TILE
ANAB

About TILE Interface Inc.

Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: